<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; NICE</title>
	<atom:link href="http://www.tapanray.in/tag/nice/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry</title>
		<link>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry</link>
		<comments>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/#comments</comments>
		<pubDate>Mon, 13 Apr 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Far Cry]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health-economics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP 2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patented Drugs Pricing]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Sloan-Kettering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[value based pricing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6530</guid>
		<description><![CDATA[Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to &#8230; <a href="http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Paying For The Best Health Outcomes At The Lowest Possible Cost</title>
		<link>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=paying-for-the-best-health-outcomes-at-the-lowest-possible-cost</link>
		<comments>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/#comments</comments>
		<pubDate>Mon, 08 Dec 2014 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Burrill]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Michael Porter]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[Outcomes. Lowest]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas Lee]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>
		<category><![CDATA[Velcade (bortezomib)]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6244</guid>
		<description><![CDATA[“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should &#8230; <a href="http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
